Pharmacotherapy for depressed pregnant women: overcoming obstacles to gathering essential data.
Approximately 3% of pregnant women take antidepressant medications. Information on the impact of antidepressants on short- and long-term maternal and offspring outcomes is highly desirable but neglected. The position that the dearth of treatment information is of greater concern than the risks to pregnant subjects involved in medical research is gaining support. Mandating the collection of reproductive outcome data in exposed childbearing women is an overdue step toward societal responsibility to our most vulnerable members.
Wisner
K L
KL
Departments of Psychiatry, Obstetrics, Gynecology and Reproductive Sciences, Epidemiology, and Women's Studies, Pittsburgh, Pennsylvania, USA. wisnerkl@upmc.edu
Appelbaum
P S
PS
Uhl
K
K
Goldkind
S F
SF
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018579:Patient Selection; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome; D015995:Prevalence; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors